KNSA Kiniksa Pharmaceuticals
WatchlistKiniksa Pharmaceuticals News
Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How
Wall Street Analysts See a 70.27% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Can the Stock Really Move This High?
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Adds US$56m to Market Cap in the Past 7 Days, Though Investors From Five Years Ago Are Still Down 25%
The main aim of stock picking is to find the market-beating stocks. But the main game is to find enough winners to more than offset the losers So we wouldn't blame long term Kiniksa Pharmaceuticals,
Promising Growth and Strategic Investments Bolster Buy Rating for Kiniksa Pharmaceuticals
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Reports Q3 Revenue $67M, Vs. Street Est of $64.4M
07:34 AM EDT, 10/31/2023 (MT Newswires) -- Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Reports Q3 Revenue $67M, vs. Street Est of $64.4M
Kiniksa Pharmaceuticals Q3 GAAP EPS $(0.20) Vs $3.18 Prior Year, Sales $67.05M Beat $64.45M Estimate
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly GAAP losses of $(0.20) per share. This is a 106.29 percent decrease over earnings of $3.18 per share from the same period last year. The compan
Earnings Scheduled For October 31, 2023
Companies Reporting Before The Bell • BBVA (NYSE:BBVA) is likely to report earnings for its third quarter. • BP (NYSE:BP) is expected to report quarterly earnings at $1.37 per share on revenue of $57.
Kiniksa Pharmaceuticals Q3 2023 Earnings Preview
Notable Earnings Before Tuesday's Open
Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023
PDF Version HAMILTON, Bermuda, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, Oc
Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Stock Is Going Strong: Is the Market Following Fundamentals?
Most readers would already be aware that Kiniksa Pharmaceuticals' (NASDAQ:KNSA) stock increased significantly by 12% over the past three months. Since the market usually pay for a company's long-ter
Kiniksa Pharmaceuticals(KNSA.US) Officer Sells US$7,012 in Common Stocks
$Kiniksa Pharmaceuticals(KNSA.US)$ Officer Paolini John F. sold 400 shares of Common Stocks on Sep 5, 2023 at an average price of $17.53 for a total value of $7,012.Source: Announcement What is statem
J.P. Morgan Sticks to Its Buy Rating for Kiniksa Pharmaceuticals (KNSA)
Insider Sell: Kiniksa Pharmaceuticals
John F. Paolini, Chief Medical Officer, on July 25, 2023, sold 29,000 shares in Kiniksa Pharmaceuticals (KNSA) for $555,160. Following the Form 4 filing with the SEC, Paolini has control over a total
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $32
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $22 to $32.
Kiniksa Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/26/2023 64.27% Goldman Sachs $22 → $32 Maintains Buy 03/09/2023 2.67% JP Morgan $19 → $20 Maintains Ove
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tarsus Pharmaceuticals (TARS), Kiniksa Pharmaceuticals (KNSA) and Danaher (DHR)
A New 52-Week High for Kiniksa Pharmaceuticals
Sector Update: Health Care Stocks Steady in Late Afternoon Trading
Health care stocks were steady late Tuesday, with the NYSE Health Care Index down less than 0.1% and the Health Care Select Sector SPDR Fund (XLV) fractionally higher. The iShares Biotechnology ETF (I
Sector Update: Health Care
Health care stocks were steady to lower late Tuesday, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both down less than 0.1%. The iShares Biotechnology ETF (IBB) wa